MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2022.12.012

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2022

A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.

Hamacher Rainer, Liu Xiaofei, Schuler Markus K, Hentschel Leopold, Schöffski Patrick, Kopp Hans-Georg, Bauer Sebastian, Kasper Bernd, Lindner Lars, Chemnitz Jens-Markus, Crysandt Martina, Stein Alexander, Steffen Björn, Richter Stephan, Egerer Gerlinde, Ivanyi Philipp, Kunitz Annegret, Grünwald Viktor

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

The EPAZ study (NCT01861951) showed recently that pazopanib was non-inferior to doxorubicin in patients ≥60 years treated in first line for advanced soft tissue sarcoma . The current post-hoc analysis aimed to assess the prognostic impact of frailty.

METHODS

Geriatric assessments were evaluated at baseline. Age >75 years, liposarcoma, ECOG = 2, G8 ≤14, instrumental activities of daily living (IADL) ≥1 and Charlson Comorbidity Index ≥2 were tested for their impact on progression-free survival (PFS), overall survival (OS), CTCAE grade 3/4 adverse events (AEs) or serious AEs (SAEs), using univariate and multivariate analysis models.

RESULTS

univariate analysis showed an increased risk of grade 3/4 AEs and SAEs for ECOG = 2, G8 score ≤14 or IADL ≥1, independent of treatment. The multivariate analysis exhibited for pazopanib a significantly reduced risk for grade 3/4 AEs (HR 0.53; p = 0.033), and in patients with G8 ≤14 an increased risk for SAEs (HR 2.67; p = 0.011). In the multivariate analysis, G8 ≤14 was a negative prognostic factor for PFS (HR 1.82; p = 0.009) and IADL ≥1 for OS (HR 2.02; p = 0.007). ECOG = 2 was the strongest negative predictor for PFS (HR 4.39; p = 0.001) and OS (HR 3.74; p = 0.004). Neither age nor Charlson Comorbidity Index showed any impact on PFS, OS, incidence of grade 3/4 AEs or SAEs.

CONCLUSIONS

This post hoc analysis demonstrated that age is not a denominator for outcome or toxicity in elderly patients with soft tissue sarcoma . Instead, geriatric and functional assessments should be used to counsel patients and tailor therapy to individual needs. Moreover, pazopanib has a reduced risk for grade 3/4 AEs compared to doxorubicin.

Для цитирования: Hamacher Rainer, Liu Xiaofei, Schuler Markus K, Hentschel Leopold, Schöffski Patrick, Kopp Hans-Georg, Bauer Sebastian, Kasper Bernd, Lindner Lars, Chemnitz Jens-Markus, Crysandt Martina, Stein Alexander, Steffen Björn, Richter Stephan, Egerer Gerlinde, Ivanyi Philipp, Kunitz Annegret, Grünwald Viktor. A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.. European journal of cancer (Oxford, England : 1990). 2022. DOI: 10.1016/j.ejca.2022.12.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.